Decolonization in Prevention of Health Care-Associated Infections

被引:175
|
作者
Septimus, Edward J. [1 ,2 ]
Schweizer, Marin L. [3 ,4 ,5 ]
机构
[1] Hosp Corp Amer, Nashville, TN USA
[2] Coll Med, Texas A&M Hlth Sci Ctr, Houston, TX USA
[3] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[4] Iowa City VA Hlth Care Syst, Iowa City, IA USA
[5] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA
关键词
RESISTANT STAPHYLOCOCCUS-AUREUS; SURGICAL-SITE INFECTIONS; IN-VITRO ACTIVITY; VENTILATOR-ASSOCIATED PNEUMONIA; BLOOD-STREAM INFECTIONS; LOW-LEVEL MUPIROCIN; CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE; POINT-PREVALENCE SURVEY; TEA TREE OIL; NASAL CARRIAGE;
D O I
10.1128/CMR.00049-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Colonization with health care-associated pathogens such as Staphylococcus aureus, enterococci, Gram-negative organisms, and Clostridium difficile is associated with increased risk of infection. Decolonization is an evidence-based intervention that can be used to prevent health care-associated infections (HAIs). This review evaluates agents used for nasal topical decolonization, topical (e.g., skin) decolonization, oral decolonization, and selective digestive or oropharyngeal decontamination. Although the majority of studies performed to date have focused on S. aureus decolonization, there is increasing interest in how to apply decolonization strategies to reduce infections due to Gram-negative organisms, especially those that are multidrug resistant. Nasal topical decolonization agents reviewed include mupirocin, bacitracin, retapamulin, povidone-iodine, alcohol-based nasal antiseptic, tea tree oil, photodynamic therapy, omiganan pentahydrochloride, and lysostaphin. Mupirocin is still the gold standard agent for S. aureus nasal decolonization, but there is concern about mupirocin resistance, and alternative agents are needed. Of the other nasal decolonization agents, large clinical trials are still needed to evaluate the effectiveness of retapamulin, povidone-iodine, alcohol-based nasal antiseptic, tea tree oil, omiganan pentahydrochloride, and lysostaphin. Given inferior outcomes and increased risk of allergic dermatitis, the use of bacitracin-containing compounds cannot be recommended as a decolonization strategy. Topical decolonization agents reviewed included chlorhexidine gluconate (CHG), hexachlorophane, povidone-iodine, triclosan, and sodium hypochlorite. Of these, CHG is the skin decolonization agent that has the strongest evidence base, and sodium hypochlorite can also be recommended. CHG is associated with prevention of infections due to Gram-positive and Gram-negative organisms as well as Candida. Conversely, triclosan use is discouraged, and topical decolonization with hexachlorophane and povidone-iodine cannot be recommended at this time. There is also evidence to support use of selective digestive decontamination and selective oropharyngeal decontamination, but additional studies are needed to assess resistance to these agents, especially selection for resistance among Gram-negative organisms. The strongest evidence for decolonization is for use among surgical patients as a strategy to prevent surgical site infections.
引用
收藏
页码:201 / 222
页数:22
相关论文
共 50 条
  • [31] Health Care-Associated Infections A Meta-analysis of Costs and Financial Impact on the US Health Care System
    Zimlichman, Eyal
    Henderson, Daniel
    Tamir, Orly
    Franz, Calvin
    Song, Peter
    Yamin, Cyrus K.
    Keohane, Carol
    Denham, Charles R.
    Bates, David W.
    JAMA INTERNAL MEDICINE, 2013, 173 (22) : 2039 - 2046
  • [32] Timeline of health care-associated infections and pathogens after burn injuries
    van Duin, David
    Strassle, Paula D.
    DiBiase, Lauren M.
    Lachiewicz, Anne M.
    Rutala, William A.
    Eitas, Timothy
    Maile, Robert
    Kanamori, Hajime
    Weber, David J.
    Cairns, Bruce A.
    Napravnik, Sonia
    Jones, Samuel W.
    AMERICAN JOURNAL OF INFECTION CONTROL, 2016, 44 (12) : 1511 - 1516
  • [33] Financial impact of health care-associated infections: When money talks
    Valiquette, Louis
    Abou Chakra, Claire Nour
    Laupland, Kevin B.
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2014, 25 (02) : 71 - 74
  • [34] Device-associated health care-associated infections: The effectiveness of a 3-year prevention and control program in the Republic of Cyprus
    Iordanou, Stelios
    Papathanassoglou, Elizabeth
    Middleton, Nicos
    Palazis, Lakis
    Timiliotou-Matsentidou, Chrystalla
    Raftopoulos, Vasilios
    NURSING IN CRITICAL CARE, 2022, 27 (04) : 602 - 611
  • [35] Health care-associated infection prevention in Japan: The role of safety culture
    Sakamoto, Fumie
    Sakihama, Tomoko
    Saint, Sanjay
    Greene, M. Todd
    Ratz, David
    Tokuda, Yasuharu
    AMERICAN JOURNAL OF INFECTION CONTROL, 2014, 42 (08) : 888 - 893
  • [36] Risk Factors for Health Care-Associated Bloodstream Infections in a Neonatal Intensive Care Unit
    Ertugrul, Sabahattin
    Aktar, Fesih
    Yolbas, Ilyas
    Yilmaz, Ahmet
    Elbey, Bilal
    Yildirim, Ahmet
    Yilmaz, Kamil
    Tekin, Recep
    IRANIAN JOURNAL OF PEDIATRICS, 2016, 26 (05)
  • [37] Health Care-Associated Infections in the Neonatal Intensive Care Unit: Barriers to Continued Success
    Bizzarro, Matthew J.
    SEMINARS IN PERINATOLOGY, 2012, 36 (06) : 437 - 444
  • [38] Health Care-Associated Infections Among Critically III Children in the US, 2007-2012
    Patrick, Stephen W.
    Kawai, Alison Tse
    Kleinman, Ken
    Jin, Robert
    Vaz, Louise
    Gay, Charlene
    Kassler, William
    Goldmann, Don
    Lee, Grace M.
    PEDIATRICS, 2014, 134 (04) : 705 - 712
  • [39] Hospital- and System-Wide Interventions for Health Care-Associated Infections: A Systematic Review
    Maurer, Nicholas R.
    Hogan, Tory H.
    Walker, Daniel M.
    MEDICAL CARE RESEARCH AND REVIEW, 2021, 78 (06) : 643 - 659
  • [40] Health care-associated infections are associated with increased length of stay and cost but not mortality in children undergoing cardiac surgery
    Tweddell, Sarah
    Loomba, Rohit S.
    Cooper, David S.
    Benscoter, Alexis L.
    CONGENITAL HEART DISEASE, 2019, 14 (05) : 785 - 790